Sam Brusco, Associate Editor02.29.24
Embolx has earned U.S. Food and Drug Administration (FDA) clearance for its Soldier high-flow microcatheter for localized drug delivery in vascular interventional procedures.
The Soldier microcatheter employs the company’s Ultra-Thin Wall (TWU) tech, which allows a smaller outer diameter for microcatheters while maintaining internal lumens that improve flow rates by almost two times. The microcatheter’s multiple, discrete longitudinal sections offer improved pushability, torquability, and trackability, according to the company.
Soldier is available in 2 and 2.5 Fr and in 130, 155, and 165 cm lengths. A strong torque response and radiopaque distal tip offer accurate curved tip placement and visualization of rotation position. With the new microcatheter platform, Embolx aims to not sacrifice image quality, distal reach, or range of embolic agents while utilizing a 2 Fr catheter.
"The FDA clearance of the Soldier microcatheter represents a significant milestone in the evolution of advanced microcatheters. With this cutting-edge technology, it is now possible to use smaller microcatheters for more embolization procedures," said Embolx president and CEO Michael Allen. "We will continue to develop innovative and unique products that provide creative solutions to therapy delivery."
The Soldier microcatheter employs the company’s Ultra-Thin Wall (TWU) tech, which allows a smaller outer diameter for microcatheters while maintaining internal lumens that improve flow rates by almost two times. The microcatheter’s multiple, discrete longitudinal sections offer improved pushability, torquability, and trackability, according to the company.
Soldier is available in 2 and 2.5 Fr and in 130, 155, and 165 cm lengths. A strong torque response and radiopaque distal tip offer accurate curved tip placement and visualization of rotation position. With the new microcatheter platform, Embolx aims to not sacrifice image quality, distal reach, or range of embolic agents while utilizing a 2 Fr catheter.
"The FDA clearance of the Soldier microcatheter represents a significant milestone in the evolution of advanced microcatheters. With this cutting-edge technology, it is now possible to use smaller microcatheters for more embolization procedures," said Embolx president and CEO Michael Allen. "We will continue to develop innovative and unique products that provide creative solutions to therapy delivery."